Congress’ investigative arm warned Wednesday (March 3) that FDA needs to prepare for a large backlog of foreign inspections in future years due to its decision to stop onsite reviews during the pandemic and rely on alternative inspection options, and it asked FDA to study whether the alternative tools have worked in place of traditional inspections. Because of this pause, FDA was not able to conduct over 1,000 facility inspections planned for 2020 and will now have to complete those...